Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Fabian Freisleben, Hauke Stamm, PhD, Jana Muschhammer, Vanessa Thaden, Franziska Modemann, MD, Alexander Krispien, Franziska Brauneck, Jasmin Wellbrock, PhD, Walter Fiedler, MD

Blood (2019) 134 (Supplement_1): 5050.

https://doi.org/10.1182/blood-2019-129973

Published: 2019

Journal Articles

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

Blood (2016) 128 (22): 2921.

https://doi.org/10.1182/blood.V128.22.2921.2921

Published: 2016

Journal Articles

HSP27: A Therapeutic Target in Myelofibrosis

Margaux Sevin, Nicolas Pernet, Franck Vitte, MD, Selim Ramla, Paul Sagot, MD PhD, Laurent Martin, MD PhD, Jean Luc Villeval, PhD, Catherine Lacout, Isabelle Plo, PhD, Carmen Garrido, PhD, Francois Girodon, MD PhD, Aurelie de Thonel, PhD

Blood (2016) 128 (22): 1963.

https://doi.org/10.1182/blood.V128.22.1963.1963

Published: 2016

Journal Articles

Do Proteasome and Heat Shock Protein Inhibitors Eliminate Leukaemia Initiating Cell Populations In Childhood ALL?

Paraskevi Diamanti, BSc, PhD, Charlotte Victoria Cox, BSc, Allison Blair, PhD, BSc

Blood (2013) 122 (21): 3912.

https://doi.org/10.1182/blood.V122.21.3912.3912

Published: 2013

Journal Articles

Anti-Apoptotic Bcl2 and Bcl-Xl Proteins Involved in Stroma-Induced Drug Tolerance to Hsp70 and Hsp90 Inhibitors in Leukemia and B-Cell Lymphoma

Eloisi Caldas Lopes, Fabian M Correa, Ling-Bo Shen, Jae-Hung Shieh, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Malcolm A.S. Moore, PhD

Blood (2012) 120 (21): 4900.

https://doi.org/10.1182/blood.V120.21.4900.4900

Published: 2012

Journal Articles

The Heatshockprotein-90 Inhibitor IPI-504 Potently Overcomes Tyrosinekinase Inhibitor-Induced Activation of Cell Protection Mechanisms and Degrades HSP-Client Proteins KIT and FLT3 In Acute Leukemia Models

Marcus Schittenhelm, Dr., MD, Tanja Grandl, Emmanuel Normant, PharmD, PhD, Helmut R. Salih, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2010) 116 (21): 3982.

https://doi.org/10.1182/blood.V116.21.3982.3982

Published: 2010

Journal Articles

Interaction Between Heat Shock Protein Inhibitors and Isoprenoid Biosynthetic Pathway Inhibitors In Multiple Myeloma Cells

Ella J. Born, BA, Sara V. Hollins, Sarah A. Holstein, MD, PhD

Blood (2010) 116 (21): 2895.

https://doi.org/10.1182/blood.V116.21.2895.2895

Published: 2010

Journal Articles

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Kerstin M Kampa, MD, Tanja Grandl, Sandra Mueller, Emmanuel Normant, PhD, Michael Walter, PhD, Wolfgang Schuetz, PhD, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD

Blood (2009) 114 (22): 2753.

https://doi.org/10.1182/blood.V114.22.2753.2753

Published: 2009

Journal Articles

SNX 2112, An Oral Hsp-90 Inhibitor Exerts Antiproliferative Effects in Combination with Bortezomib and Rituximab in Rituximab Resistant Non-Hodgkin's Lymphoma.

Nishitha Reddy, MD, Donna Hicks, BS, Madan Jagasia, MD, MS, Kathy Amiri, PhD

Blood (2009) 114 (22): 3733.

https://doi.org/10.1182/blood.V114.22.3733.3733

Published: 2009

Journal Articles

Heat Shock Protein Inhibition in Sickle Cell Disease: A Novel Approach to Attenuating the Inflammatory Response?.

Kavita Natarajan, MBBS, John Catravas, PhD, Joseph Cannon, PhD, Tao Li, MD, Ferdane Kutlar, MD, Gloria Sloan, Sabine Fields, RN, Betsy Clair, Abdullah Kutlar, MD

Blood (2007) 110 (11): 2263.

https://doi.org/10.1182/blood.V110.11.2263.2263

Published: 2007

Journal Articles

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene Ghobrial, MD

Blood (2005) 106 (11): 2413.

https://doi.org/10.1182/blood.V106.11.2413.2413

Published: 2005

Journal Articles

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

Alissa Huston, MD, Alexey Leontovich, MD, Michael Timm, MD, Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Ganwei Lu, PhD, Judy Anderson, Suzanne Lentzsch, MD, Irene Ghobrial, MD

Blood (2005) 106 (11): 3402.

https://doi.org/10.1182/blood.V106.11.3402.3402

Published: 2005

Journal Articles

Hsp90 Expression in Acute Myeloid Leukaemia.

Elisabeth J. Walsby, Amanda F. Gilkes, Valerie Walsh, Kenneth I. Mills, Alan K. Burnett

Blood (2004) 104 (11): 4471.

https://doi.org/10.1182/blood.V104.11.4471.4471

Published: 2004

Journal Articles

Depletion of the Intracellular Akt Kinase, and Its Downstream Signaling, Mediates Synergy between the Proteasome Inhibitor MG-132 and the Heat Shock Protein 90 Inhibitor 17-AAG in the Multiple Myeloma Cell Line U266.

Christopher Maisel, M.D., Nizar Bahlis, M.D., Yanling Miao, Lili Liu, M.D., Stanton Gerson, M.D.

Blood (2004) 104 (11): 3364.

https://doi.org/10.1182/blood.V104.11.3364.3364

Published: 2004

NARROW

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

HSP27: A Therapeutic Target in Myelofibrosis

Do Proteasome and Heat Shock Protein Inhibitors Eliminate Leukaemia Initiating Cell Populations In Childhood ALL?

Anti-Apoptotic Bcl2 and Bcl-Xl Proteins Involved in Stroma-Induced Drug Tolerance to Hsp70 and Hsp90 Inhibitors in Leukemia and B-Cell Lymphoma

The Heatshockprotein-90 Inhibitor IPI-504 Potently Overcomes Tyrosinekinase Inhibitor-Induced Activation of Cell Protection Mechanisms and Degrades HSP-Client Proteins KIT and FLT3 In Acute Leukemia Models

Interaction Between Heat Shock Protein Inhibitors and Isoprenoid Biosynthetic Pathway Inhibitors In Multiple Myeloma Cells

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

SNX 2112, An Oral Hsp-90 Inhibitor Exerts Antiproliferative Effects in Combination with Bortezomib and Rituximab in Rituximab Resistant Non-Hodgkin's Lymphoma.

Heat Shock Protein Inhibition in Sickle Cell Disease: A Novel Approach to Attenuating the Inflammatory Response?.

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

Hsp90 Expression in Acute Myeloid Leukaemia.

Depletion of the Intracellular Akt Kinase, and Its Downstream Signaling, Mediates Synergy between the Proteasome Inhibitor MG-132 and the Heat Shock Protein 90 Inhibitor 17-AAG in the Multiple Myeloma Cell Line U266.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only